Pharmaceutical giant GSK has hiked its 2031 sales forecast to more than £40bn, up from £38bn, after reporting better than ...
This week saw two major life sciences investments in London, as GSK unveiled plans to move its headquarters to a central location in the city, while an ambitious plan to develop a new biosciences ...
GlaxoSmithKline "deliberately" discontinued a widely-used asthma medication in order to reap profits and families suffered, ...
Shares of GSK Plc. were gaining around 6 percent on the London Stock Exchange, as well as in the pre-market activity on the NYSE, ...
The Shanghai Composite fell 0.7% in afternoon trade. It was the first time the Shanghai market re-opened after the Chinese New Year break. The Hang Seng Index in Hong Kong was down 0.9%. Tokyo's ...
Pharma giant GSK surged to the top of the index as it missed forecasts slightly with its annual results, but raised its ...
The long-running HIV market rivalry between Gilead Sciences and GSK is about to turn a new page this year as Gilead looks to ...
The FTSE 100 index rose 12.01 points, 0.1%, at 8,582.78. The FTSE 250 declined 30.17 points, 0.2%, at 20,623.09. It traded off session lows, however. The AIM All-Share rose 0.72 of a point, 0.1%, at ...
London stocks nudged higher in early trade on Wednesday as investors mulled disappointing US tech results and continued to ...
European markets opened mixed on Wednesday, with investors looking ahead to more earnings from a number of key companies.
British pharmaceutical group GSK on Wednesday reported a near halving of net profit in 2024 after settling hefty US lawsuits over its Zantac heartburn drug.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback